Key facts
- This page summarizes Christopher Peetz's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jan 2022, 15:54.
Christopher Peetz - 06 Jan 2022 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- MIRM
- Reported as of
- 06 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2022, 15:54:24 UTC
- Prior SEC filing
- 04 Jan 2022
- Next SEC filing
- 12 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jody Howe, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Peetz filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 07 Jan 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- +143%
- Price
- $0.000000
- Shares after
- 68,027
- Date
- 06 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
MIRM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 201,570
- Date
- 06 Jan 2022
- Ownership
- By The Peetz Family Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRM
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +240,000
- Change %
- Price
- $0.000000
- Shares after
- 240,000
- Date
- 06 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 240,000
- Exercise price
- $15.87
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
Footnote F2
1/4th of the shares vest one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.